Lipocine (LPCN) Proxy Filing summary

Executive summary

• The annual meeting is scheduled for June 4, 2025, at the company’s Salt Lake City office, with six key proposals up for shareholder vote, including director elections, auditor ratification, executive compensation, a reduction in authorized shares, and potential adjournment to solicit votes.

• Shareholders of record as of April 7, 2025, are eligible to vote, with one vote per share; a quorum requires one-third of outstanding shares.

• Proxy materials are primarily distributed via internet access to reduce costs and environmental impact.

Voting matters and shareholder proposals

• Six directors are nominated for election to serve until the 2026 annual meeting.

• Ratification of Tanner LLC as independent auditor for 2025 is proposed.

• Advisory approval of executive compensation (say-on-pay) is included.

• Proposal to amend the certificate of incorporation to reduce authorized common shares from 200,000,000 to 75,000,000.

• Proposal to adjourn the meeting if necessary to solicit additional votes.

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• The board consists of six members, with a majority classified as independent.

• Board leadership separates the roles of CEO and Chairman, with a Lead Independent Director providing additional oversight.

• Board diversity matrix shows gender and ethnic diversity among directors.

• Audit and Compensation Committees are established; no separate Nominating Committee, as the full board handles nominations.

• Directors attended over 75% of meetings in 2024; a Code of Ethics and Insider Trading Policy are in place.